NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

\

Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania

  • Author:
  • Origin:
  • Time of issue:2023-03-15
  • Views:2527

Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania

  • Author:
  • Origin:
  • Time of issue:2023-03-15
  • Views:2527

(LOWER GWYNEDD, Pennsylvania, March 15, 2023) Tavotek Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs, was named a finalist for the 2022 Emerging Company of the Year Award by Life Sciences Pennsylvania.


The Emerging Company of the Year Award recognizes a company or organization that has experienced significant growth and/or achievement in 2022, while contributing positively to its community and the overall life sciences business climate of the Commonwealth.


Dr. Mark Chiu, Chief Scientific Officer said, “We are thrilled to be named a finalist for the Emerging Company of the Year Award. This recognition is a testament to our hard work and dedication to advancing life sciences and positively contributing to our community.” 


About Tavotek


Tavotek Biotherapeutics is a multi-specific antibody drug company with the world's cutting-edge protein engineering technology, focusing on oncology and immunology diseases. The company's R&D is mainly built on three innovative breakthrough technology platforms, namely: TavoSelectTM, a bacteriophage biobank with AI assisted 3D selection; TavoPreciseTM, a sophisticated protein engineering platform that supports the development of bispecific and multi-specific antibodies, and TavoELITETM, an innovative synthetic biologic platform focusing on overcoming intracellular undruggable targets with particular focus on protein-protein interaction. With unique innovative R&D capabilities, biomarker-driven clinical development strategies, and efficient execution efficiency, Tavotek will provide treatment options with better efficacy, safety and convenience to advance medical care for patients.


Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Launching First-In-Human Study of Two Assets In 2022
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces FDA Clearance of FIH Clinical Trial for TAVO412
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

727 Norristown Road, 3 Spring House Innovation Park Suite 101, Lower Gwynedd, Pennsylvania 19002

China. Suzhou. Suzhou Industrial Park. Unit 405, Building C2, No. 218, Xinghu Street

© 2023 Tavotek Biotherapeutics All rights reserved.   (267) 405-9426

© 2023 Tavotek Biotherapeutics All rights reserved.(267) 405-9426